← Companies|Retrophin (Zevra)
Re

Retrophin (Zevra)

San Diego CAFounded 2011120 employees
Private CapbiotechAcquiredRare Disease
Platform: Thiola
Market Cap
N/A
All Drugs
2
Clinical Trials
4
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (2 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
LiravorutinibRET-8421Preclinical2MultispecificUSP1PI3KiGISTPBC
TerafutibatinibRET-9812Phase 2/32Gene EditingTYK2Anti-AβPAH
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)
2027-06-25
Terafutibatinib Ph3 Readout
PAH
Ph3 Readout
2028-05-02
Liravorutinib Interim
GIST
Interim
2028-12-26
Liravorutinib Interim
GIST
Interim